Nanoengineered virus-mimics as templates for design of a universal influenza A va
Nanoengineered virus-mimics as templates for design of a universal influenza A va
批准号:
8499243
负责人:
Harvinder Singh Gill
金额:
$13.26万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-27 至 2015-05-31
关键词:
AdjuvantAffectAmino AcidsAnimal ModelAntigensB-LymphocytesCellsChargeChildCommunicable DiseasesCysteineDataDevelopmentDrug FormulationsEconomic BurdenElderlyEnzyme-Linked Immunosorbent AssayEpithelial CellsFigs - dietaryFutureGenesGoalsGoldHIVHIV-1High Pressure Liquid ChromatographyImmuneImmune responseImmunityImmunizationImmunoglobulin GInfluenzaInfluenza A Virus, H1N1 SubtypeIntramuscularIsoelectric PointLifeM2 proteinMagnetismMeasuresMembrane ProteinsMethodologyMonitorMorbidity - disease rateMorphologyMucosal ImmunityMusMutationN-terminalNanotechnologyNasal Lavage FluidNosePenetrationPeptidesPhilippinesPlayPropertyRoleRouteSalivaSerumSolutionsStructureSulfhydryl CompoundsSurfaceSystemTechniquesTechnologyTestingTransmission Electron MicroscopyVaccinationVaccinesVirionVirusVirus Diseasesabsorptionanti-influenzabasecell mediated immune responsedensitydesignextracellularflexibilityimmunogenicimprovedinfluenza virus vaccineinfluenzavirusmucosal vaccinenanoengineeringnanoparticleneuronal cell bodynovelpandemic diseaseparticleprotective efficacyresearch studyrespiratoryresponsevaccine deliveryvaccine developmentzeta potential
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Influenza virus causes serious respiratory illness and has potential to cause pandemics. Due to the high mutation rate in influenza genes, antigenic drift creates a new strain each year. Consequently there is significant economic burden to monitor virus activity and to create and distribute new influenza vaccines to the public each year. On the surface of the influenza A virion is found a highly conserved membrane protein (M2) which lends itself as a potential target for developing a universal influenza vaccine. However, under natural circumstances, M2 is present in very small numbers (16-22 per virus particles), is not well exposed at the virus surface and is poorly immunogenic. Our approach to overcome these challenges is to emulate virus structure through the use of a synthetic gold (Au) nanoparticle (AuNP) conjugated with different functional peptides creating a nanoengineered virus-mimic (NVM). The NVM can carry an antigen of choice in high density. In addition, other functional peptides can also be easily attached to the NVM. For example, peptides that can enable NVMs to enter cells or to activate the immune cells of the body could be attached. Based on the NVM concept, we propose to develop a universal influenza A vaccine delivery system. As the influenza antigen we have selected the highly conserved extracellular portion of the influenza-A matrix protein M2 (M2e), and as the cell-penetrating peptide to enhance entry of NVMs into cells we have selected tat (47-58) peptide derived from the human immunodeficiency virus (HIV-1). Our hypothesis is that NVMs presenting a high density of M2e on their surface with tat as a helper peptide can stimulate a broadly protective anti-influenza A immune response. The objectives of this study are to optimize NVMs as an influenza vaccine system and to evaluate their protective efficacy in mice animal models using live infectious challenges with heterologous and heterosubtypic influenza strains. Importantly we will evaluate systemic and mucosal B cell immunity for the intranasal routes of immunization. This project is novel because it seeks to exploit nanotechnology to create a modular vaccine delivery system, which like 'lego' pieces, can be used to assemble NVMs with unique functionalities. This concept can be used broadly used to create vaccine delivery systems against a host of infectious diseases.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
共有的M2E肽与金纳米颗粒结合的肽赋予了针对H1N1,H3N2和H5N1流感病毒的保护。
DOI:
10.1016/j.antiviral.2017.01.021
发表时间:
2017-05
期刊:
Antiviral research
影响因子:
7.6
作者:
[Tao W, Hurst BL, Shakya AK, Uddin MJ, Ingrole RS, Hernandez-Sanabria M, Arya RP, Bimler L, Paust S, Tarbet EB, Gill HS]
通讯作者:
Gill HS
DOI:
10.1016/j.jconrel.2016.02.014
发表时间:
2016-10-28
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
[Shakya AK, Chowdhury MYE, Tao W, Gill HS]
通讯作者:
Gill HS
Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.
金纳米粒子-M2E与CPG共轭偶联物可诱导对流感病毒的保护性免疫。
DOI:
10.2217/nnm.13.58
发表时间:
2014-02
期刊:
Nanomedicine (London, England)
影响因子:
--
作者:
[Tao W, Ziemer KS, Gill HS]
通讯作者:
Gill HS
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
-
批准号:10053298
-
项目类别:
-
资助金额:$68.9万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Microneedles for treatment of peanut allergy
-
批准号:9662551
-
项目类别:
-
资助金额:$71.85万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
-
批准号:10291415
-
项目类别:
-
资助金额:$68.74万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Microneedles for treatment of peanut allergy
-
批准号:10219057
-
项目类别:
-
资助金额:$64.98万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
-
批准号:10519103
-
项目类别:
-
资助金额:$66.8万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Microneedles for treatment of peanut allergy
-
批准号:10471226
-
项目类别:
-
资助金额:$63.27万
-
财政年份:2018
-
负责人:Harvinder Singh Gill
-
依托单位:
Engineering an intranasal universal influenza vaccine
-
批准号:9526306
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2017
-
负责人:Harvinder Singh Gill
-
依托单位:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
-
批准号:8285558
-
项目类别:
-
资助金额:$21.51万
-
财政年份:2012
-
负责人:Harvinder Singh Gill
-
依托单位:
POLLEN GRAINS AS TROJAN HORSES FOR ORAL VACCINATION
-
批准号:8356940
-
项目类别:
-
资助金额:$220.5万
-
财政年份:2012
-
负责人:Harvinder Singh Gill
-
依托单位:
Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
-
批准号:8249376
-
项目类别:
-
资助金额:$10.61万
-
财政年份:2011
-
负责人:Harvinder Singh Gill
-
依托单位:
Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
-
批准号:8141631
-
项目类别:
-
资助金额:$10.59万
-
财政年份:2011
-
负责人:Harvinder Singh Gill
-
依托单位:
海外基金